Labiotech.eu

News and Trends 30 Jun 2022

LG Chem renews license triggering $2M payment to Avacta

South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal fee to UK-based oncology drug company Avacta Group plc. of $2 million. Avacta develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms. Under the terms of the agreement, LG Chem has the exclusive rights to develop […]

June 30, 2022 - 2 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […]

June 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

Acticor Biotech gets patent for cardiovascular emergency treatment product

French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036. The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both […]

June 30, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Jun 2022

Evolved By Nature raises $120M for biotech silk technology

Evolved By Nature, the company creating a library of Activated Silk molecules from natural silk protein, has closed $120M in Series C financing. The round was led by Teachers’ Venture Growth (TVG), part of the C$242 billion Ontario Teachers’ Pension Plan Board, and Senator Investment Group, with participation from existing investors including Mousse Partners, Chanel, […]

June 30, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 30 Jun 2022

Funding doubled for company working on breakthrough auto-immune disease therapeutics

A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it has almost doubled its initial funding from two companies. The initial funding for Ermium Therapeutics of €6.3 million ($6.57 million) now stands at €12.3 million ($12.83 million) and has been supplied by Kurma Partners and Fountain Healthcare Partners. Ermium discovers […]

June 30, 2022 - 3 minutesmins - By Liza Laws

mereo biopharma brittle bone disease osteogenesis imperfecta

News and Trends 30 Jun 2022

Sirana Pharma and Pfizer to work on treatment for brittle bone disease

German biotech company Sirana Pharma GmbH has entered into a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease, osteogenesis imperfecta (OI). Also called brittle bone disease, the condition is currently lacking approved drugs. Sirana Pharma focuses on the development of […]

June 30, 2022 - 2 minutesmins - By Jim Cornall

Inside Labiotech 30 Jun 2022

Meet Aurore and Liza, our new team members

Making conscious career decisions can be one of the biggest challenges we face, but having a clear aim and core values helps align our life paths to what matters the most to us. With a strong passion in SEO and growth hacking, our new Growth Marketing Manager Aurore was seeking new challenges to use her […]

June 30, 2022 - 8 minutesmins - By Yi-Jen Chang

decentralized trial virtual clinical trial

News and Trends 29 Jun 2022

Global call for scientists and inventors to form new startup

A fourth start-up but the first of its kind sees some high-profile companies join forces in a hunt for new global research talent. AION Labs, an Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) are focusing their start-up on the ‘prediction of clinical trial outcome in biomarker-stratified cancer patient […]

June 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jun 2022

Drug for childhood arthritis gets expanded approvals in the EU

A drug that can reduce the risk of flare and disease activity in children with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) has been approved based on data from a clinical trial. The JUNIPERA trial, showing that Cosentyx (secukinumab) reduced the risk of flare and disease activity compared to placebo over two years in pediatric patients with […]

June 29, 2022 - 4 minutesmins - By Liza Laws

News and Trends 29 Jun 2022

ARCH Venture Partners launches $3B fund for biotech companies

ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. The new fund follows the January 2021 announcement of the $1.941 billion ARCH Venture Fund XI. “All the fundamental innovations in biotechnology are accelerating, with huge promise […]

June 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jun 2022

Encouraging results from respiratory diseases vaccine trial

A biopharmaceutical company developing vaccines against infectious diseases has announced positive results for people with life threatening respiratory diseases. Icosavax says that in an interim phase 1/1b trial its vaccine IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no […]

June 29, 2022 - 4 minutesmins - By Liza Laws

PBC clinical trials: Gannex doses first patient

News and Trends 29 Jun 2022

Deal to advance treatment for autoimmune disease worth $97M

MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […]

June 29, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

LG Chem renews license triggering $2M payment to Avacta

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

Acticor Biotech gets patent for cardiovascular emergency treatment product

Evolved By Nature raises $120M for biotech silk technology

Funding doubled for company working on breakthrough auto-immune disease therapeutics

Sirana Pharma and Pfizer to work on treatment for brittle bone disease

Meet Aurore and Liza, our new team members

Global call for scientists and inventors to form new startup

Drug for childhood arthritis gets expanded approvals in the EU

ARCH Venture Partners launches $3B fund for biotech companies

Encouraging results from respiratory diseases vaccine trial

Deal to advance treatment for autoimmune disease worth $97M

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!